Deep-Dive Due Diligence AI Generated Probe of Hepion Pharmaceuticals, Inc. Common Stock (HEPA)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These auto-generated reports apply OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.


HEPA_OUT_1 [2025-04-01 12:25:22 -0400] 2053 Bytes | 550 tokens | Cum: 550 tkns (6.88% of 8k)
==========================================================================

Booyah, my friends! It's already 12:25:22 PM on Tue Apr 01, 2025 -0400, and I've got my eyes locked on Hepion Pharmaceuticals (HEPA), pushing up to 0.5381 from 0.4299. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for Hepion Pharmaceuticals:

C1 - Mar-14-25 12:15PM - Biotech Alert: Searches spiking for these stocks today
C2 - Mar-14-25 12:15PM 08:30AM - Hepion Pharmaceuticals Announces Reverse Stock Split
C3 - Jan-22-25 08:00AM - Hepion Pharmaceuticals Announces $9.0 Million Public Offering
C4 - Dec-11-24 08:00AM - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
C5 - Dec-05-24 08:30AM - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group
C6 - Dec-02-24 08:00AM - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
C7 - Nov-11-24 08:00AM - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger
C8 - Sep-04-24 09:25AM - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Hepion Pharmaceuticals (HEPA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

HEPA_IN_2 [2025-04-01 12:25:22 -0400] 2 Bytes | 2 tokens | Cum: 552 tkns (6.90% of 8k)
==========================================================================

C2

HEPA_OUT_3 [2025-04-01 12:25:26 -0400] 1106 Bytes | 332 tokens | Cum: 884 tkns (11.05% of 8k)
==========================================================================

Showing C2 (chunk 1 of 9): C2:
**Hepion Pharmaceuticals Announces Reverse Stock Split**
Date: Mar-14-25 12:15PM 08:30AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/14/3042959/0/en/Hepion-Pharmaceuticals-Announces-Reverse-Stock-Split.html

March 14, 2025 08:30 ET| Source:Hepion Pharmaceuticals, Inc.Hepion Pharmaceuticals, Inc.

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025

MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it will implement a 1-for-50 reverse split of the issued shares of its common stock, effective at 4:01 p.m. Eastern Time on March 17, 2025. The Company's common stock is exp

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_IN_4 [2025-04-01 12:25:26 -0400] 366 Bytes | 85 tokens | Cum: 969 tkns (12.11% of 8k)
==========================================================================

Hepion Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for chronic liver diseases, has announced a 1-for-50 reverse stock split of its common shares. The reverse split will become effective at 4:01 p.m. Eastern Time on March 17, 2025. The company's shares are expected to start trading on a split-adjusted basis from March 18, 2025.

HEPA_OUT_5 [2025-04-01 12:25:27 -0400] 896 Bytes | 281 tokens | Cum: 1250 tkns (15.62% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T13:48:08Z - HEPA stock plunges to 52-week low, touches $0.67 By Investing.com...
A2 - 2025-03-25T13:47:29Z - HEPA stock plunges to 52-week low, touches $0.67 By Investing.com...
A3 - 2025-03-25T13:48:08Z - HEPA stock plunges to 52-week low, touches $0.67 By Investing.com...
A4 - 2025-03-17T05:31:13Z - Upcoming Stock Splits This Week (March 17 to March 21) - Stay Invested...
A5 - 2025-03-14T20:35:05Z - U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.65% By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HEPA_IN_6 [2025-04-01 12:25:27 -0400] 2 Bytes | 2 tokens | Cum: 1252 tkns (15.65% of 8k)
==========================================================================

A1

HEPA_OUT_7 [2025-04-01 12:25:32 -0400] 1098 Bytes | 307 tokens | Cum: 1559 tkns (19.49% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**HEPA stock plunges to 52-week low, touches $0.67 By Investing.com**Date: 2025-03-25Source: {'uri': 'uk.investing.com', 'dataType': 'news', 'title': 'Investing.com UK'}URL: https://uk.investing.com/news/company-news/hepa-stock-plunges-to-52week-low-touches-067-93CH-3996297In a tumultuous turn of events, Contravir Pharmaceuticals, trading as HEPA, has seen its stock price plummet to a 52-week low, reaching a mere $0.67. According to InvestingPro analysis, the stock's RSI indicates oversold territory, while the company's overall financial health score stands at a concerning 0.95, labeled as 'WEAK'. This significant drop is a stark reflection of the challenges the company has faced over the past year, with the stock experiencing a staggering 1-year change of -99.38%. The company's EBITDA stands at -$25.32M, with concerning cash burn rates as evidenced by negative free cash flow of -$26

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_IN_8 [2025-04-01 12:25:32 -0400] 486 Bytes | 117 tokens | Cum: 1676 tkns (20.95% of 8k)
==========================================================================

Based on the information provided, Contravir Pharmaceuticals, trading as HEPA, has faced severe financial difficulties over the past year. The company's stock price has hit a 52-week low of $0.67, marking a decrease of -99.38% in a year. Additionally, the firm's financial health score is worryingly low at 0.95, indicating weak financial stability. The company's EBITDA stands at -$25.32M, and it's also showing high cash burn rates, as evidenced by a negative free cash flow of -$26M.

HEPA_OUT_9 [2025-04-01 12:25:33 -0400] 975 Bytes | 286 tokens | Cum: 1962 tkns (24.52% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-11T13:00:00Z - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
B2 - 2024-12-02T13:00:00Z - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
B3 - 2024-04-19T20:30:00Z - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
B4 - 2024-03-06T13:30:00Z - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
B5 - 2024-02-16T13:00:00Z - Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
B6 - 2024-01-03T22:15:00Z - Hepion Pharmaceuticals to Present at NASH-TAG 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HEPA_IN_10 [2025-04-01 12:25:33 -0400] 2 Bytes | 2 tokens | Cum: 1964 tkns (24.55% of 8k)
==========================================================================

B1

HEPA_OUT_11 [2025-04-01 12:25:36 -0400] 757 Bytes | 208 tokens | Cum: 2172 tkns (27.15% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/11/2995333/0/en/Hepion-Pharmaceuticals-Inc-Announces-Termination-of-Merger-Agreement-with-Pharma-Two-B-Ltd.htmlHepion Pharmaceuticals has terminated its merger agreement with Pharma Two B Ltd. and has withdrawn proposals for a special stockholder meeting. The company is continuing efforts to provide value from its drug candidate rencofilstat to shareholders.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_IN_12 [2025-04-01 12:25:36 -0400] 279 Bytes | 53 tokens | Cum: 2225 tkns (27.81% of 8k)
==========================================================================

Hepion Pharmaceuticals has ended its merger agreement with Pharma Two B Ltd. The company has also withdrawn proposals for a special stockholder meeting. Despite these changes, Hepion is still striving to deliver value to its shareholders through its drug candidate, rencofilstat.

HEPA_OUT_13 [2025-04-01 12:25:36 -0400] 488 Bytes | 155 tokens | Cum: 2380 tkns (29.75% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2024-11-14 10-Q PART IFIN INFO

Item 1. Condensed Cons Fin Stmnts

HEPION PHARMACEUTICALS, INC. & SUBSIDIARIES

COND CONS BAL SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Curr assets: Cash $ 1,497,106 $ 14,785,880 Pr...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HEPA_IN_14 [2025-04-01 12:25:36 -0400] 2 Bytes | 2 tokens | Cum: 2382 tkns (29.78% of 8k)
==========================================================================

S1

HEPA_OUT_15 [2025-04-01 12:25:51 -0400] 1098 Bytes | 344 tokens | Cum: 2726 tkns (34.08% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART IFINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

HEPION PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2024 December 31, 2023 Assets Current assets: Cash $ 1,497,106 $ 14,785,880 Prepaid expenses 1,433,186 2,701,960 Related party receivable 600,000 Total current assets 3,530,292 17,487,840 Property and equipment, net 29,487 Right-of-use assets 118,301 212,878 Other assets 66,505 364,192 Total assets $ 3,715,098 $ 18,094,397 Liabilities and Stockholders Equity Current liabilities: Accounts payable $ 186,259 $ 2,348,829 Accrued expenses 306,000 2,439,351 Operating lease liabilities, current 117,952 115,916 Notes payable, current 2,105,753 Short-term portion of contingent consideration 386,000 Total current liabilities 2,715,964 5,290,096 Contingent consideration, non-current 1,634,000 Oper

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_IN_16 [2025-04-01 12:25:51 -0400] 1206 Bytes | 282 tokens | Cum: 3008 tkns (37.60% of 8k)
==========================================================================

According to the unaudited condensed consolidated balance sheets of Hepion Pharmaceuticals, Inc. and its subsidiaries, as of September 30, 2024, the company had total assets of $3,715,098. This is a significant decrease from the total assets worth $18,094,397 as of December 31, 2023. The major contributors to the total assets in September 2024 were cash amounting to $1,497,106, prepaid expenses of $1,433,186, and related party receivable of $600,000.

In terms of liabilities and stockholders equity, the company had total current liabilities of $2,715,964 as of September 30, 2024, which is also a decrease from the total current liabilities of $5,290,096 as of December 31, 2023. Significant current liabilities included accounts payable of $186,259, accrued expenses of $306,000, operating lease liabilities of $117,952, notes payable of $2,105,753, and the short-term portion of contingent consideration of $386,000. The company also had non-current contingent consideration amounting to $1,634,000.

The decrease in both total assets and total liabilities may imply that the company may have used its assets to pay off its liabilities. However, more detailed analysis is required to confirm this.

HEPA_OUT_17 [2025-04-01 12:25:58 -0400] 1098 Bytes | 325 tokens | Cum: 3333 tkns (41.66% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ating lease liabilities, non-current 93,104 Derivative financial instruments-warrants 1,405,819 3,796,390 Total liabilities 4,121,783 10,813,590 Commitments and contingencies (see Note 12) - Stockholders equity: Series A convertible preferred stock, stated value $ 10 per share, 85,581 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 855,808 855,808 Series C convertible preferred stock, stated value $ 1,000 per share, 1,688 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 839,320 839,320 Convertible preferred stock 839,320 839,320 Common stock$ 0.0001 par value per share; 120,000,000 shares authorized, 6,958,371 and 4,818,733 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 663 482 Additional paid-in capital 234,223,707 230,291,362 Accumulated other comprehensive loss ( 53,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

HEPA_IN_18 [2025-04-01 12:25:58 -0400] 701 Bytes | 167 tokens | Cum: 3500 tkns (43.75% of 8k)
==========================================================================

The data presented is a portion of the balance sheet showing the liabilities and stockholders' equity of a company. The total liabilities of the company amount to 4,121,783 and 10,813,590 at two different points in time.

The company has issued Series A and Series C convertible preferred stocks valued at 855,808 and 839,320 respectively, with no changes over the period. The number of common stocks issued and outstanding at September 30, 2024, and December 31, 2023 were 6,958,371 and 4,818,733 respectively. The additional paid-in capital has increased from 230,291,362 to 234,223,707. The company also has an accumulated other comprehensive loss, but the exact figure is not shown in this chunk.

HEPA_OUT_19 [2025-04-01 12:26:10 -0400] 4134 Bytes | 1177 tokens | Cum: 4677 tkns (58.46% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+-----------------------+
| Volume: 8,031,095 | Perf Month: -90.43% | Option/Short: No / No | Sales Y/Y TTM: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| Avg Volume: 1.12M | Perf Quarter: -97.65% | Short Float: 14.91% | ROE: -288.27% |
+--------------------+-----------------------+-----------------------+-----------------------+
| Rel Volume: 16.31 | Index: - | Short Ratio: 0.14 | ROI: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| RSI (14): 21.41 | Market Cap: 0.58M | Short Interest: 0.16M | Sales Surprise: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| ATR (14): 0.66 | Shs Outstand: 1.08M | Beta: 1.80 | EPS Surprise: -17.54% |
+--------------------+-----------------------+-----------------------+-----------------------+
| SMA20: -68.98% | Shs Float: 1.07M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| SMA50: -90.89% | Inst Own: 2.89% | Sales past 5Y: 0.00% | Earnings: - |
+--------------------+-----------------------+-----------------------+-----------------------+
| SMA200: -98.11% | Insider Own: 0.48% | Employees: - | |
+--------------------+-----------------------+-----------------------+-----------------------+
| Perf Week: -24.26% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+-----------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -4865948.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.5496
Average Volume: 2304788.87
30-Day High: 5.64
30-Day Low: 0.4299

[Detailed Financials: Q3 2024]
- Total Assets: $3,715,098.0
- Total Liabilities: $4,121,783.0
- Total Equity: $-406,685
- Current Assets: $3,530,292.0
- Current Liabilities: $2,715,964.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.72

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $14,495,592.0

[Detailed Financials: Q2 2024]
- Total Assets: $6,010,164.0
- Total Liabilities: $2,448,334.0
- Total Equity: $3,561,830.0
- Current Assets: $5,482,409.0
- Current Liabilities: $975,634

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.68

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-14,433,832.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

HEPA_IN_20 [2025-04-01 12:26:10 -0400] 1199 Bytes | 270 tokens | Cum: 4947 tkns (61.84% of 8k)
==========================================================================

1) Brief Summary:
The company has experienced severe declines in performance over the past month and quarter, with a 90.43% and 97.65% drop respectively. This is reflected in a heavily oversold RSI of 21.41 and a significant drop in the SMA20, SMA50, and SMA200. The average volume has significantly increased, suggesting heightened interest or activity, likely due to the declines. The company's ROE is at a staggering -288.27% and it appears to have no sales growth in the past 5 years. The Market Cap is extremely low at 0.58M and the share outstanding is 1.08M. The net income is negative and there is no information about revenue. Furthermore, the company has more liabilities than assets which indicates financial distress.

2) MARKET_SCORE[20]:
Given the company's poor financial health and the significant downward trend in performance, the likelihood of an upward move in the near future seems low.

3) PRICE_TARGET[$0.60]:
Considering the company's current state, it seems unlikely that there will be a significant increase in price. However, a small rebound could be possible due to the oversold condition.

4) AI_RPT_HEADLINE: "Company Faces Severe Decline Amidst Financial Distress"

HEPA_OUT_21 [2025-04-01 12:26:11 -0400] 676 Bytes | 167 tokens | Cum: 5114 tkns (63.92% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

HEPA_IN_22 [2025-04-01 12:26:11 -0400] 31 Bytes | 7 tokens | Cum: 5121 tkns (64.01% of 8k)
==========================================================================

-> X6 <- More financial metrics

HEPA_IN_23 [2025-04-01 12:26:11 -0400] 126 Bytes | 29 tokens | Cum: 5150 tkns (64.38% of 8k)
==========================================================================

====================================
[2025-04-01 12:26:11] # Analysis Completed
Elapsed Time: 49.88 seconds




Scroll to Top